Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.


Clinical Trial Description

Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor (PDE5i). Since PDE5i is known to relax smooth muscle cells, it is suggested that PDE5i may dilate cerebral vessels and lead to an increase in cerebral blood flow. The main mechanism of subcortical vascular cognitive impairment are hypoperfusion of the brain. Therefore, in this study, the investigators will investigate whether Udenafil can increase cerebral blood flow and also lower peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01466543
Study type Interventional
Source Samsung Medical Center
Contact Hyunhee Jung, BSc
Phone 82-2-3410-6830
Email napapaya@hanmail.net
Status Not yet recruiting
Phase Phase 2
Start date November 2011
Completion date November 2012

See also
  Status Clinical Trial Phase
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Not yet recruiting NCT06416371 - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Completed NCT01761227 - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Phase 2
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT00165763 - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Phase 4
Completed NCT00621647 - Seroquel- Agitation Associated With Dementia Phase 3
Recruiting NCT04095962 - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia N/A
Recruiting NCT03275363 - The University of Hong Kong Neurocognitive Disorder Cohort N/A
Active, not recruiting NCT03804229 - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Phase 3
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Completed NCT02453932 - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Phase 3
Completed NCT00947531 - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Phase 4
Not yet recruiting NCT03702543 - Managing Vascular Dementia Risk Factors With SymTrend Phase 1
Enrolling by invitation NCT02147652 - Personalized Music Therapy and Agitation in Dementia N/A
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA
Recruiting NCT06034509 - Cognitive and Vascular Functioning Following TBI
Recruiting NCT05921266 - Urolithin A Supplementation in Middle-aged Adults With Obesity N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A